COVID-19 vaccine effectiveness
If you want to see all comparisons, please click here
BNT162b2 primed with ChAdOx1-S vs No vaccine
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
|Trial||Type||Comparisons||Design||Participants||Sample size||Overall risk
|Intervention 1||Intervention 2|
Pfizer/BioNTech + Fosun Pharma
Borobia A M, Lancet, 2021
|RNA based vaccine||
|RCTPhase 2||Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain.||N=676||